Psychemedics Corp (PMD) 15.26 $PMD
Psychemedics Corporation Announces Record Revenues
PR Newswire - Tue Feb 10, 9:50AM CST
Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 23, 2015 to be paid on March 6, 2015. This will be the Company's 74th consecutive quarterly dividend.
PMD: 15.26 (-0.14)
5 Small-Cap Health Care Stocks You Never Heard of But Should Consider for 2015
at The Street - Mon Feb 02, 7:39AM CST
The health care equipment and supplies may not seem like the sexiest of places to invest, but the sector has a positive outlook, according to TheStreet Ratings.
PMD: 15.26 (-0.14), IRIX: 9.95 (unch), FONR: 12.19 (+0.05), DRAD: 4.50 (+0.08), SPAN: 18.30 (-0.15), KEQU: 17.50 (-0.12)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
Update: Psychemedics Corp. Q3 Earnings
Bram de Haas - at Seeking Alpha - Thu Nov 20, 2:30PM CST
PMD: 15.26 (-0.14)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.26 (-0.14), ABT: 46.09 (+0.87), A: 40.15 (+0.13), DHR: 86.81 (+0.21), PKI: 46.30 (-0.10), OSUR: 8.13 (+0.06)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 15.26 (-0.14)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 15.26 (-0.14)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 15.26 (-0.14)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93.
PMD: 15.26 (-0.14)
Psychemedics Corporation Announces Record Revenues
PR Newswire - Tue Feb 10, 9:50AM CST
Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 23, 2015 to be paid on March 6, 2015. This will be the Company's 74th consecutive quarterly dividend.
PMD: 15.26 (-0.14)
5 Small-Cap Health Care Stocks You Never Heard of But Should Consider for 2015
at The Street - Mon Feb 02, 7:39AM CST
The health care equipment and supplies may not seem like the sexiest of places to invest, but the sector has a positive outlook, according to TheStreet Ratings.
PMD: 15.26 (-0.14), IRIX: 9.95 (unch), FONR: 12.19 (+0.05), DRAD: 4.50 (+0.08), SPAN: 18.30 (-0.15), KEQU: 17.50 (-0.12)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
Update: Psychemedics Corp. Q3 Earnings
Bram de Haas - at Seeking Alpha - Thu Nov 20, 2:30PM CST
PMD: 15.26 (-0.14)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 15.26 (-0.14), ABT: 46.09 (+0.87), A: 40.15 (+0.13), DHR: 86.81 (+0.21), PKI: 46.30 (-0.10), OSUR: 8.13 (+0.06)
Psychemedics: Recent Results Reflect Risk Of The Brazilian Expansion
Investing Doc - at Seeking Alpha - Tue Nov 04, 7:21AM CST
PMD: 15.26 (-0.14)
Psychemedics EPS of $0.17
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 10:14AM CDT
PMD: 15.26 (-0.14)
Psychemedics: Once Brazilian Legislation Is Put Into Place Shares Should Rally
Bram de Haas - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PMD: 15.26 (-0.14)
Psychemedics Has Returned 13.0% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Sep 17, 9:26AM CDT
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on May 9th, 2014 at $14.87. In approximately 4 months, Psychemedics has returned 13.05% as of today's recent price of $12.93. PMD: 15.26 (-0.14)
